Issue link: https://www.e-digitaleditions.com/i/1527415
The industry organizations page of the Inhalation website provides descriptions and contact information for cross-industry organizations and groups that present educational conferences and workshops. Inhalation OctOber 2024 33 CALENDAR Please visit the industry orga- nizations page of the Inhalation website to find descriptions and contact information for cross- industry organizations and groups that present educational confer- ences and workshops. https://www.inhalationmag.com/ industry-organizations Results were published in Lancet Respiratory Medicine. Participants received either Vicks First Defence gel-based nasal spray, a saline nasal spray or an online resource promot- ing physical activity and stress man- agement. Patients in all three groups experienced a 25% reduction in the number of days with severe symp- toms and antibiotic use, while both nasal sprays shortened the duration of the illness by 20%, resulting in a reduction in days off from work up to 30%, while the exercise and stress reduction group experienced a 5% reduction in symptoms. "Our results show nasal sprays work well to reduce the duration and severity of respiratory infections, and the interference with normal activi- ties," said study leader Paul Little, Professor in Primary Care Research, University of Southampton. [e] "reduction in the use of antibiotics is also potentially very important in the fight against antibiotic resis- tance, one of the major public health threats of our time." RESPIRATORY MEDICINE NEWS continued from page 8 for self-administration in the US. e approval allows FLUMIST to be used by adults up to 49 years of age or administered by a parent/ caregiver to individuals 2-17 years of age. A company news release explained that individuals 18 and older will be able to have FLUMIST delivered directly to their homes. e program will utilize an online pharmacy where eligible individu- als complete a questionnaire that is reviewed by a pharmacist prior to receiving their vaccine. FLUMIST will continue to be available in phy- sician offices and pharmacies for administration by healthcare profes- sionals. e release also stated that seasonal influenza causes up to 1 bil- lion infections each year and may result in severe outcomes for about three to five million patients includ- ing hospitalizations, complications and death. Vaccination rates for influenza have declined in adults in the US since the 2020–2021 season. In a US survey, a common reason for adults not to receive a vaccination included failure to attend regular well-care visits, while having access to at-home vaccination options were shown to potentially increase influ- enza vaccination uptake. Study finds OTC nasal sprays reduced RTI severity and antibiotic use SOUTHAMPTON, UNITED K I N G D O M — P h a r m aT i m e s Online and the University of South- ampton News reported results from study of nearly 14,000 adults from 322 GP practices that showed over- the-counter nasal sprays could help to reduce the severity of upper respi- ratory tract infections (RTIs) as well as use of antibiotics. e study was led by researchers from the Univer- sity of Southampton in partner- ship with the University of Bristol and funded by the National Insti- tute for Health and Care Research. • Centrally manage all projects, apparatuses, and testing protocols. • Create re-usable workflow templates for all testing, analytics, and reporting. • Supports all USP / Ph. Eur. apparatuses and configurations. Fully supports 21 CFR 11 compliance. • Full bi-directional CDS automation for ChemStation, Chromeleon ™ , and Empower ™ . • Companion module for formulation and device design R&D. Fusion Inhaler Testing Software ™ The Only Fully Automated Software Solution for Oral and Nasally Inhaled Drug Product R&D and QC www.smatrix.com sales@smatrix.com